We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 409.6999 -1.5286% AAPL 222.71 -1.8034% NVDA 128.3057 2.7103% GOOGL 163.14 -2.3465% GOOG 164.6592 -2.3142% AMZN 180.47 -3.2384% META 585.16 -1.8089% AVGO 175.79 -0.4812% TSLA 241.6955 -3.3527% TSM 183.57 1.3303% LLY 899.35 1.374% V 273.29 -1.6695% JPM 209.74 -0.7007% UNH 585.745 -0.9227% NVO 117.48 2.05% WMT 79.45 -1.8409% LVMUY 149.27 1.7519% XOM 125.47 0.5127% LVMHF 747.0 1.8335% MA 491.24 -1.298%

Morphic Holding Inc

Healthcare US MORF

NoneUSD
-(-%)

Last update at 2024-09-26T03:06:11.318019Z

Day Range

--
LowHigh

52 Week Range

19.3463.08
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap1541.63M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-191.96899M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -31.25400M
  • Diluted EPS TTM-3.59

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -58.97400M -95.54200M -45.56900M -42.41600M -23.83100M
Minority interest - - - - -
Net income -59.04100M -94.24000M -44.99900M -43.32800M -23.83100M
Selling general administrative 32.14M 27.81M 18.50M 10.23M 5.36M
Selling and marketing expenses - - - - -
Gross profit 70.81M 19.79M 44.95M 16.98M 3.36M
Reconciled depreciation 1.00M 1.03M 1.13M 0.82M 0.54M
Ebit -64.40100M -96.83600M -48.30600M -46.98800M -24.62800M
Ebitda -63.39600M -95.80600M -47.18000M -46.16700M -24.08900M
Depreciation and amortization 1.00M 1.03M 1.13M 0.82M 0.54M
Non operating income net other - - 1.61M - -
Operating income -63.39600M -95.80600M -47.18000M -46.98800M -24.62800M
Other operating expenses 134.20M 115.60M 92.12M 63.97M 27.99M
Interest expense 4.57M 0.27M 2.74M 4.57M 0.00000M
Tax provision 0.07M 0.00000M -0.57000M 0.91M 0.00000M
Interest income 4.57M 0.27M 1.63M 4.67M 0.87M
Net interest income 4.57M 0.27M 1.63M 4.67M 0.87M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M -1.30200M -0.57000M 0.91M 0.80M
Total revenue 70.81M 19.79M 44.95M 16.98M 3.36M
Total operating expenses 134.20M 115.60M 92.12M 63.97M 27.99M
Cost of revenue - - - 53.73M 22.63M
Total other income expense net 4.42M 0.26M 1.61M 4.57M -0.07400M
Discontinued operations - - - - -
Net income from continuing ops -59.04100M -95.54200M -44.99900M -43.32800M -23.83100M
Net income applicable to common shares -59.04100M -95.54200M -44.99900M -43.32800M -23.83100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 722.51M 368.59M 426.29M 242.38M 247.44M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 12.58M 13.93M 10.20M 11.17M 3.09M
Total liab 25.49M 19.47M 89.59M 97.19M 106.52M
Total stockholder equity 697.02M 349.12M 336.70M 145.20M 140.92M
Deferred long term liab - - - 57.75M -
Other current liab 17.08M 11.69M 11.63M 39.44M 6.73M
Common stock 0.00500M 0.00400M 0.00400M 0.00300M 0.00300M
Capital stock 0.00500M 0.00400M 0.00400M 0.00300M 0.00300M
Retained earnings -449.19000M -297.09500M -238.05400M -142.51200M -97.51300M
Other liab - - 51.33M 57.75M 71.17M
Good will - - - - -
Other assets - 0.77M 7.96M 0.34M 0.42M
Cash 58.58M 59.27M 408.13M 228.26M 101.56M
Cash and equivalents - - - - -
Total current liabilities 24.78M 17.13M 38.26M 39.44M 35.35M
Current deferred revenue -1.62800M 0.47M 20.63M 25.27M 23.45M
Net debt -56.23300M -55.43400M -403.08600M -228.26400M -101.55900M
Short term debt 1.63M 1.49M 1.21M -29.11100M -
Short long term debt - - - - -
Short long term debt total 2.34M 3.84M 5.05M - -
Other stockholder equity 1143.92M 649.55M 575.23M 287.73M -9.05100M
Property plant equipment - 5.63M 7.39M 2.61M 3.45M
Total current assets 716.93M 362.18M 418.33M 239.44M 243.57M
Long term investments - - - - -
Net tangible assets - 349.12M 336.70M 145.20M 140.92M
Short term investments 645.77M 288.98M 236.70M 126.22M 135.46M
Net receivables 0.00000M 0.46M 2.31M 7.31M 3.47M
Long term debt - - - - -
Inventory - -0.45500M -2.30700M -7.31400M -
Accounts payable 7.70M 3.48M 4.80M 3.85M 5.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.29M -3.33900M -0.48200M -0.02100M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00300M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -142.51200M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.13M 0.77M 0.57M 0.34M 0.42M
Deferred long term asset charges - - - - -
Non current assets total 5.59M 6.41M 7.96M 2.95M 3.86M
Capital lease obligations 2.34M 3.84M 5.05M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -56.45100M -112.16000M 8.72M -135.98600M -0.65600M
Change to liabilities -69.20000M -13.85100M -9.01600M 0.93M 97.50M
Total cashflows from investing activities -56.45100M -113.18000M 8.18M -135.98600M -0.65600M
Net borrowings - - - - -0.65200M
Total cash from financing activities 45.27M 266.31M 38.30M 93.30M 89.47M
Change to operating activities -5.59500M -2.50800M 2.76M 1.35M 1.05M
Net income -59.04100M -95.54200M -44.99900M -43.32800M -23.83100M
Change in cash -112.16200M 69.67M 0.49M -84.34200M 165.15M
Begin period cash flow 171.99M 102.32M 101.83M 186.18M 21.02M
End period cash flow 59.83M 171.99M 102.32M 101.83M 186.18M
Total cash from operating activities -100.97700M -83.46100M -45.99000M -41.65100M 76.34M
Issuance of capital stock 39.21M 265.22M 33.65M 93.27M 90.12M
Depreciation 1.00M 1.03M 1.13M 0.82M 0.54M
Other cashflows from investing activities - - - -133.82800M 0.00300M
Dividends paid - - - - -
Change to inventory - -2.50800M 2.83M 1.41M -
Change to account receivables 1.85M 5.01M -3.84700M -3.46700M -3.46700M
Sale purchase of stock 0.89M 1.09M 1.11M 93.30M 90.12M
Other cashflows from financing activities 5.17M -113.18000M 3.53M 0.03M 90.12M
Change to netincome 30.00M 22.40M 11.05M 2.04M 1.07M
Capital expenditures 0.36M 1.02M 0.54M 2.16M 0.66M
Change receivables - - -3.84700M - -
Cash flows other operating - - -0.75700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 0.49M - -
Change in working capital -72.94300M -11.35200M -13.62000M -1.18700M 98.56M
Stock based compensation 29.05M 21.18M 11.05M 3.53M 1.00M
Other non cash items 0.95M 1.22M 0.45M -0.02200M 0.04M
Free cash flow -101.34200M -84.48100M -46.53400M -43.80900M 75.68M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MORF
Morphic Holding Inc		 - -% - - - 2752.53 2.06 1405.11 -4.1221
NVO
Novo Nordisk A/S		 2.36 2.05% 117.48 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.56 3.12% 117.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.645 1.24% 449.67 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -15.105 1.49% 997.72 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Morphic Holding Inc

35 Gatehouse Drive, A2, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Dr. Praveen P. Tipirneni M.D. CEO, MD & Director 1968
Dr. Bruce N. Rogers Ph.D. Pres 1969
Dr. Timothy A. Springer Ph.D. Founder, Independent Director & Member of Scientific Advisory Board 1948
Dr. Marc Schegerin M.B.A., M.D. CFO & COO 1976
Mr. William D. DeVaul Esq. Gen. Counsel & Sec. 1971
Mr. Robert E. Farrell Jr., CPA, CPA Sr. VP of Fin. & Operations and Chief Accounting Officer 1965
Dr. Blaise Lippa Ph.D. Chief Scientific Officer NA
Mr. Aaron Pelta Sr. VP of Bus. & Corp. Devel. NA
Ms. Joanne Gibbons Sr. VP of Regulatory Affairs NA
Dr. Bruce N. Rogers Ph.D. President & Interim Principal Executive Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.